English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Levetiracetam in patients with central neuropathic post-stroke pain: A randomized, double-blind, placebo-controlled trial

Jungehulsing, G. J., Israel, H., Safar, N., Taskin, B., Nolte, C., Brunecker, P., et al. (2013). Levetiracetam in patients with central neuropathic post-stroke pain: A randomized, double-blind, placebo-controlled trial. European Journal of Neurology, 20(2), 331-337. doi:10.1111/j.1468-1331.2012.03857.x.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-0013-A838-B Version Permalink: http://hdl.handle.net/21.11116/0000-0003-8581-4
Genre: Journal Article

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Jungehulsing, G. J.1, 2, Author
Israel, H.1, Author
Safar, N.1, Author
Taskin, Birol1, 3, Author              
Nolte, C.1, 2, Author
Brunecker, P.2, Author
Wernecke, K.-D.4, Author
Villringer, Arno1, 2, 3, Author              
Affiliations:
1Department of Neurology, Charité University Medicine Berlin, Germany, ou_persistent22              
2Center for Stroke Research, Charité University Medicine Berlin, Germany, ou_persistent22              
3Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society, ou_634549              
4Institute of Medical Biometrics and Clinical Epidemiology, Charité University Medicine Berlin, Germany, ou_persistent22              

Content

show
hide
Free keywords: Antiepileptic drugs; Central pain; Levetiracetam; Neuropathic pain; Randomized clinical trial; Stroke
 Abstract: Background and purpose Central post-stroke pain (CPSP) is a severe chronic neuropathic pain condition defined as a spontaneous pain or allodynia corresponding to a vascular lesion. It usually evolves weeks after stroke, and can distinctively impair the quality of life. Treatment is complex and mostly unsatisfactory. We hypothesized that the anti-epileptic drug levetiracetam (LEV) improves CPSP compared with placebo. The purpose of this study was to examine the efficacy and tolerability of LEV in patients with CPSP. Methods In a double-blind, placebo-controlled, crossover study design patients with CPSP lasting at least 3 months and a pain score ≥ 4 on the 11-point Likert scale were treated over two 8-week periods with a maximum dose up to 3000 mg LEV or placebo. Primary endpoint was a median pain lowering ≥ 2 in the final treatment week compared with the last baseline week. Secondary outcome measures comprised additional pain ratings, depression, sleep quality, quality of life and patients' global impression of change. Results Of 42 patients, 33 [61.5 years (40–76); 38% women] completed the study. Side effects and withdrawals were more frequent in the LEV (n = 5) group than in the placebo group (n = 1). Patients treated with LEV did not show any improvement of pain or changes in secondary outcome parameters compared with placebo. Conclusions LEV is not effective in treatment for CPSP. The mode of action of LEV does not exert an analgesic effect in chronic CPSP.

Details

show
hide
Language(s): eng - English
 Dates: 2012-03-082012-07-122012-08-272013-02
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: Peer
 Identifiers: DOI: 10.1111/j.1468-1331.2012.03857.x
PMID: 22925226
Other: Epub 2012
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: European Journal of Neurology
  Other : Eur. J. Neurol.
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Oxford : Rapid Communications
Pages: - Volume / Issue: 20 (2) Sequence Number: - Start / End Page: 331 - 337 Identifier: ISSN: 1351-5101
CoNE: https://pure.mpg.de/cone/journals/resource/954925617087